KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.Adil Daud, Georgina V. Long, Jose Lutzky et al.|Journal of Clinical Oncology|2016Cited by 15
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutationMichele Maio, Omid Hamid, Matteo S. Carlino et al.|European Journal of Cancer|2021Cited by 10
Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic reviewSudha Rajagopal, Teresa M. Petrella, Xiaomei Yao et al.|Surgical Oncology|2024Cited by 6
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative IntentSudha Rajagopal, Teresa M. Petrella, Xiaomei Yao et al.|Clinical Oncology|2024Cited by 4